Indication
Breast Cancer, Stage IV
68 clinical trials
105 products
27 drugs
Clinical trial
A Phase I Dose Escalation Trial of Alpha-Tocopheryloxyacetic Acid (α-TEA) in Patients With Treatment Refractory HER2+ Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2024-02-01
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)Status: Withdrawn, Estimated PCD: 2026-05-31
Drug
AtezolizumabDrug
UTD1Clinical trial
Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based TherapyStatus: Active (not recruiting), Estimated PCD: 2024-07-30
Product
AnastrozoleProduct
DenifanstatProduct
ExemestaneProduct
FulvestrantClinical trial
Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2027-08-15
Clinical trial
Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast CancerStatus: Completed, Estimated PCD: 2023-12-31
Drug
AlpelisibProduct
EnzalutamideClinical trial
Phase 1b/2 Study of Naxitamab (Danyelza), Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells in Advanced GD2-expressing Breast Cancers (DiG NKs)Status: Recruiting, Estimated PCD: 2024-12-31
Drug
GemcitabineDrug
NaxitamabProduct
LetrozoleDrug
TiragolumabDrug
TrastuzumabClinical trial
A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer PatientsStatus: Completed, Estimated PCD: 2022-10-13
Product
PalbociclibClinical trial
A Phase II Study of Intratumorally Injected Autologous Dendritic Cells (DCs) in PD-L1-Negative Treatment Naïve and in Refractory Metastatic Triple Negative Breast Cancer PatientsStatus: Not yet recruiting, Estimated PCD: 2026-10-01
Product
PembrolizumabClinical trial
A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2025-03-01
Product
AbemaciclibDrug
TamoxifenProduct
EstradiolClinical trial
A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination With Endocrine Therapy in Patients Age 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 InhibitionStatus: Recruiting, Estimated PCD: 2024-08-21
Drug
AN0025Clinical trial
Therapeutic Targeting of ER Beta in Triple Negative Breast CancerStatus: , Estimated PCD: 2026-07-31
Product
CobimetinibProduct
VinorelbineProduct
VismodegibDrug
EntrectinibProduct
EribulinClinical trial
A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable DiseaseStatus: Recruiting, Estimated PCD: 2025-01-09
Clinical trial
PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer and PD1/PD-L1 Inhibitor-Refractory MelanomaStatus: Recruiting, Estimated PCD: 2024-11-01
Product
Neoantigen Peptide VaccineClinical trial
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxStatus: Recruiting, Estimated PCD: 2026-09-01
Product
NivolumabProduct
Poly ICLCClinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)Status: Recruiting, Estimated PCD: 2025-02-24
Drug
cyclophosphamideClinical trial
A Pilot, Single-Arm, Phase II Trial of Tamoxifen Plus Pegylated Liposomal Doxorubicin in Patients With Metastatic Triple Negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2028-06-30
Clinical trial
A Phase IIa Study of Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab in Patients With Asymptomatic Brain Metastasis From Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)Status: Recruiting, Estimated PCD: 2025-06-15
Clinical trial
Impact of Beta-2 Adrenergic Blockade With Checkpoint Inhibition in Checkpoint Inhibitor Refractory Metastatic Triple Negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-12-15
Product
PropranololProduct
CabozantinibDrug
AbraxaneDrug
FOLFOXIRIProduct
Recombinant Flt3 LigandClinical trial
Olaparib Plus Low-Dose Alpelisib for Breast Cancer: A ComboMATCH Treatment TrialStatus: Withdrawn, Estimated PCD: 2025-04-30
Drug
AlpelisibProduct
OlaparibClinical trial
Safely Stopping Pre-Medications in Patients Receiving Paclitaxel: A Randomized TrialStatus: Recruiting, Estimated PCD: 2024-12-31
Product
CimetidineProduct
NiraparibProduct
PertuzumabClinical trial
A Phase II Trial of Stereotactic Body Radiation Therapy and Fluoroestradiol Positron Emission Tomography in Patients With Oligoprogressive Estrogen Receptor Positive Metastatic Breast CancerStatus: Not yet recruiting, Estimated PCD: 2025-12-11
Clinical trial
Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Product
CarboplatinClinical trial
A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumetinib or Capivasertib, or Ceralasertib Monotherapy in Patients With Metastatic Triple-Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Product
CapivasertibDrug
CeralasertibProduct
DurvalumabProduct
SelumetinibClinical trial
Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pimasertib for Treatment of Intracranial MetastasesStatus: Completed, Estimated PCD: 2023-12-08
Product
Bintrafusp AlfaProduct
PimasertibClinical trial
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Triple Negative Breast Cancer (TNBC)Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
IpilimumabProduct
Vaccine TherapyProduct
GemcitabineProduct
TremelimumabClinical trial
Novel Dynamic PET Kinetics and MRI Radiomics Analyses in Brain TumorsStatus: Completed, Estimated PCD: 2023-09-18
Product
18F-FMAUClinical trial
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2021-04-22
Product
EntinostatClinical trial
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage ResponseStatus: Recruiting, Estimated PCD: 2024-12-01
Product
TalazoparibClinical trial
A Phase 1B Trial Evaluating the Safety of Ribociclib, Tucatinib, and Trastuzumab in Patients With Metastatic, HER2+ Breast Cancer and a Multicenter, Randomized, Open-Label, Phase 2 Study of Preoperative Treatment With Ribociclib,Ttrastuzumab, Tucatinib, and Fulvestrant Versus Docetaxel, Carboplatin,Ttrastuzumab, and Pertuzumab in HR+/HER2+ Breast Cancer and Ribociclib, Trastuzumab, and Tucatinib Versus Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab in Patients With HR-/HER2+ Breast CancerStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
tGLI1 as a Therapeutic Target in Brain Metastases: A Window of Opportunity Study in Breast Cancer Brain Metastases and Primary GliomasStatus: Recruiting, Estimated PCD: 2024-07-01
Product
KetoconazoleDrug
DocetaxelProduct
RibociclibDrug
TucatinibProduct
DexamethasoneClinical trial
A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination With Balstilimab in Patients With Metastatic Triple Negative Breast Cancer With Expansion Cohort in PD-L1 Negative TNBCStatus: Recruiting, Estimated PCD: 2026-10-01
Product
IvermectinProduct
BalstilmabClinical trial
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/YearStatus: Recruiting, Estimated PCD: 2025-01-31
Product
MemantineClinical trial
Phase I/II Safety and Efficacy Study of Autophagy Inhibition With Hydroxychloroquine to Augment the Antiproliferative and Biological Effects of Pre-Operative Palbociclib Plus Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast CancerStatus: Completed, Estimated PCD: 2024-04-17
Product
HydroxychloroquineProduct
Trastuzumab EmtansineClinical trial
Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2025-02-03
Product
AvapritinibProduct
DiphenhydramineProduct
VemurafenibProduct
FamotidineClinical trial
Phase 1 Feasibility Trial: Improved Staging of Lobular Breast Cancer With Novel Amino Acid Metabolic and Tumor Neovasculature Receptor ImagingStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
Fluciclovine F18Clinical trial
IRENE Study: Phase 2 Study of INCMGA00012 and the Oncolytic Virus Pelareorep in Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-06-30
Product
PelareorepProduct
RetifanlimabProduct
GozetotideClinical trial
A Phase I, First-in-Human Study of Intratumoral Administration of CF33-hNIS-antiPDL1, A Novel Chimeric Oncolytic Poxvirus Encoding Human Sodium Iodide Symporter (HNIS) in Patients With Metastatic Triple Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-09-22
Clinical trial
REINA: A Phase I Study of Radiation Enhanced IL 12-Necrosis Attraction in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer PatientsStatus: Withdrawn, Estimated PCD: 2022-02-16
Product
Immunocytokine NHS-IL12Clinical trial
Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients With Metastatic Triple-Negative Inflammatory Breast CancerStatus: Terminated, Estimated PCD: 2023-12-19
Product
DasatinibClinical trial
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast CancerStatus: Active (not recruiting), Estimated PCD: 2020-05-05
Product
AlectinibDrug
LHRH agonistProduct
GoserelinClinical trial
Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast CancerStatus: Recruiting, Estimated PCD: 2025-03-31
Product
CediranibClinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIMEStatus: Terminated, Estimated PCD: 2020-12-10
Product
DabrafenibProduct
RanitidineClinical trial
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV InfectionStatus: Active (not recruiting), Estimated PCD: 2025-11-02
Product
AbirateroneProduct
AfatinibDrug
T-VECProduct
BicalutamideClinical trial
Phase 2 Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Inactivating or Inferred Inactivating NF1 Alterations: A ComboMATCH Treatment TrialStatus: Recruiting, Estimated PCD: 2026-11-01
Product
BinimetinibClinical trial
Molecular Analysis for Combination Therapy Choice (ComboMATCH)Status: Recruiting, Estimated PCD: 2030-07-01
Product
BortezomibProduct
CabazitaxelClinical trial
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to DocetaxelStatus: Active (not recruiting), Estimated PCD: 2022-07-25
Product
AZD8186Drug
fluorouracilProduct
IpatasertibDrug
mFOLFOX6Product
NeratinibProduct
NilotinibProduct
DacomitinibProduct
DarolutamideClinical trial
Phase Ib/II Trial of Copanlisib in Combination With Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) With PIK3CA Mutation or PTEN MutationStatus: Terminated, Estimated PCD: 2022-04-29
Product
CopanlisibClinical trial
A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast CancerStatus: , Estimated PCD: 2025-12-31
Product
ZEN-3694Product
PanitumumabProduct
SotorasibDrug
CelecoxibClinical trial
ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MAGE-A1-Specific T-Cell Receptor (TCR) Combined With Atezolizumab in Patients With Metastatic MAGE-A1 Expressing CancerStatus: Terminated, Estimated PCD: 2022-08-04
Drug
fludarabineProduct
PD1 InhibitorDrug
R-CHOPProduct
EnasidenibClinical trial
A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 InhibitorStatus: Withdrawn, Estimated PCD: 2022-02-19
Drug
ErlotinibClinical trial
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer: A Phase II Study of Panitumumab (PmAb) and Pembrolizumab (Pembro) in Combination With Neoadjuvant Chemotherapy (NAC) in Patients With Newly Diagnosed Triple Negative Inflammatory Breast Cancer (TN-IBC)Status: Withdrawn, Estimated PCD: 2023-07-26
Clinical trial
Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)Status: Recruiting, Estimated PCD: 2026-03-31
Product
Trastuzumab DeruxtecanClinical trial
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain MetastasesStatus: Recruiting, Estimated PCD: 2025-02-17
Product
Sacituzumab GovitecanClinical trial
A Phase 1b Study of Talimogene Laherparepvec (T-VEC) in Combination With Chemotherapy or Endocrine Therapy in Patients With Metastatic, Unresectable, or Locoregionally Recurrent HER2-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Drug
TucidinostatClinical trial
A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination With Olaparib in Patients With BRCA1/2-Mutant TumorsStatus: Withdrawn, Estimated PCD: 2026-12-06
Product
MagrolimabProduct
Talimogene LaherparepvecProduct
Nab paclitaxelClinical trial
A Phase I/IB Study of Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Patients With Metastatic Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2023-01-21
Clinical trial
Epigenetic Priming for Immune Therapy in ER-Positive Breast Cancer in Biomarker Select PopulationStatus: Terminated, Estimated PCD: 2023-06-15
Product
VorinostatClinical trial
Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-06-30
Product
Interferon Alpha-2Clinical trial
An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated NeuropathyStatus: Recruiting, Estimated PCD: 2030-05-31
Product
PlaceboDrug
RintatolimodClinical trial
Single Arm Study to Assess the Immune Effects of Fermented Wheat Germ (FWG) Nutritional Supplementation in Patients With Advanced Malignancies Being Treated With Standard of Care Checkpoint Inhibitor-Based TherapyStatus: Recruiting, Estimated PCD: 2025-06-02
Product
Fermented Wheat Germ ExtractClinical trial
Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary CancerStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination With Copanlisib in Patients With Metastatic Triple Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-Associated Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Product
VeliparibClinical trial
An Early Phase I Study of the Pharmacodynamics of WEE1 Inhibitor, ZN-c3, in Metastatic Solid TumorsStatus: Withdrawn, Estimated PCD: 2024-09-30
Product
Wee1 Inhibitor ZN-c3Clinical trial
A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination With Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine-Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)Status: Active (not recruiting), Estimated PCD: 2023-06-22
Clinical trial
Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast CancerStatus: , Estimated PCD: 2027-02-23
Product
Decitabine and Cedazuridine